Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Zhejiang Conba Pharmaceutical Co's FCF Margin % or its related term are showing as below:
SHSE:600572'
s FCF Margin % Range Over the Past 10 Years
Min: 2.29 Med: 10.66 Max: 14.39
Current: 13.13
During the past 13 years, the highest FCF Margin % of Zhejiang Conba Pharmaceutical Co was 14.39%. The lowest was 2.29%. And the median was 10.66%.
SHSE:600572's FCF Margin % is ranked better than 77.88% of 963
companies
in the Drug Manufacturers industry
Industry Median: 2.57
vs SHSE:600572: 13.13
Zhejiang Conba Pharmaceutical Co FCF Margin % Related Terms
Zhejiang Conba Pharmaceutical Co FCF Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhejiang Conba Pharmaceutical Co FCF Margin % Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Zhejiang Conba Pharmaceutical Co's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zhejiang Conba Pharmaceutical Co FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Zhejiang Conba Pharmaceutical Co's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Zhejiang Conba Pharmaceutical Co's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhejiang Conba Pharmaceutical Co (SHSE:600572) has a FCF Margin % of 10.91% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Zhejiang Conba Pharmaceutical Co and its competitors. This is near median its historical median of 10.66. Over the past decade, Zhejiang Conba Pharmaceutical Co's FCF Margin % has ranged from 2.29 to 14.39. According to the industry distribution chart, Zhejiang Conba Pharmaceutical Co ranks #213 out of 963 companies in the Drug Manufacturers industry, placing it in the top 22.1%.
Is Zhejiang Conba Pharmaceutical Co's FCF Margin % too high?
Zhejiang Conba Pharmaceutical Co's current FCF Margin % of 10.91% is near median its 10-year median of 10.66. Over the past 10 years, this metric has ranged from a low of 2.29 to a high of 14.39. The Drug Manufacturers industry median FCF Margin % is 2.57. Zhejiang Conba Pharmaceutical Co's value of 10.91% is 324.5% above this industry median. Based on the distribution chart, Zhejiang Conba Pharmaceutical Co ranks #213 out of 963 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Zhejiang Conba Pharmaceutical Co has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zhejiang Conba Pharmaceutical Co's FCF Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Zhejiang Conba Pharmaceutical Co ranks #213 out of 963 companies for FCF Margin %. This places Zhejiang Conba Pharmaceutical Co in the top 22% of its industry — outperforming the majority of peers. The industry median FCF Margin % is 2.57. Zhejiang Conba Pharmaceutical Co's value of 10.91% is 324.5% above this benchmark. Historically, Zhejiang Conba Pharmaceutical Co's own FCF Margin % has ranged from 2.29 to 14.39 over the past decade. While the company's 10-year median is 10.66 vs. the industry median of 2.57, Zhejiang Conba Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.57, based on 963 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zhejiang Conba Pharmaceutical Co's current FCF Margin % of 10.91% is 324.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Zhejiang Conba Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zhejiang Conba Pharmaceutical Co's current FCF Margin % is 10.91%, which is near median its own 10-year median of 10.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhejiang Conba Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Zhejiang Conba Pharmaceutical Co (SHSE:600572) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥5.51, compared to a current price of ¥4.32 — trading 21.6% below its estimated fair value. The current FCF Margin % is 10.91%, which is near median its 10-year median of 10.66 and 324.5% above the Drug Manufacturers industry median of 2.57. Zhejiang Conba Pharmaceutical Co's overall GF Score™ is 71/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Zhejiang Conba Pharmaceutical Co (SHSE:600572), the current FCF Margin % is 10.91% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zhejiang Conba Pharmaceutical Co (SHSE:600572) Overvalued in 2026?
Based on GuruFocus' analysis, Zhejiang Conba Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥4.32 is trading 21.6% below its estimated GF Value™ of ¥5.51.
GuruFocus considers Zhejiang Conba Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for SHSE:600572:
FCF Margin %: 10.91% (near median its 10-year median of 10.66)
GF Value™: ¥5.51 vs. price of ¥4.32 (21.6% below fair value)
Industry Position: 324.5% above the Drug Manufacturers median (#213 of 963)
No single metric tells the full story. See the SHSE:600572 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zhejiang Conba Pharmaceutical Co Business Description
Zhejiang Conba Pharmaceutical Co Ltd operates as a pharmaceutical company in China. It offers traditional Chinese medicines, botanical extracts, chemical medicines, chemical raw medicines, health foods, common foods, prepared drugs in pieces, and commodities. It provides its products under the Conba, Prostate Plus, Zhenshiming, Tianbaoning, Alocin, Xitao, Yuanbang, Baby, and Omeprazole names.
71GF Score
Get the complete analysis for SHSE:600572
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600572 has been successfully added to your 
